Literature DB >> 28329704

The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity.

Juan L Mendoza1, William M Schneider2, Hans-Heinrich Hoffmann2, Koen Vercauteren2, Kevin M Jude1, Anming Xiong3, Ignacio Moraga1, Tim M Horton1, Jeffrey S Glenn3, Ype P de Jong4, Charles M Rice2, K Christopher Garcia5.   

Abstract

Type III interferons (IFN-λs) signal through a heterodimeric receptor complex composed of the IFN-λR1 subunit, specific for IFN-λs, and interleukin-10Rβ (IL-10Rβ), which is shared by multiple cytokines in the IL-10 superfamily. Low affinity of IL-10Rβ for cytokines has impeded efforts aimed at crystallizing cytokine-receptor complexes. We used yeast surface display to engineer a higher-affinity IFN-λ variant, H11, which enabled crystallization of the ternary complex. The structure revealed that IL-10Rβ uses a network of tyrosine residues as hydrophobic anchor points to engage IL-10 family cytokines that present complementary hydrophobic binding patches, explaining its role as both a cross-reactive but cytokine-specific receptor. H11 elicited increased anti-proliferative and antiviral activities in vitro and in vivo. In contrast, engineered higher-affinity type I IFNs did not increase antiviral potency over wild-type type I IFNs. Our findings provide insight into cytokine recognition by the IL-10R family and highlight the plasticity of type III interferon signaling and its therapeutic potential.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28329704      PMCID: PMC5510750          DOI: 10.1016/j.immuni.2017.02.017

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  59 in total

1.  Evolution of a cytokine using DNA family shuffling.

Authors:  C C Chang; T T Chen; B W Cox; G N Dawes; W P Stemmer; J Punnonen; P A Patten
Journal:  Nat Biotechnol       Date:  1999-08       Impact factor: 54.908

2.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

Review 3.  Chronic hepatitis D at a standstill: where do we go from here?

Authors:  Alessia Ciancio; Mario Rizzetto
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-10       Impact factor: 46.802

4.  The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities.

Authors:  Eyal Kalie; Diego A Jaitin; Yulia Podoplelova; Jacob Piehler; Gideon Schreiber
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

5.  Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity.

Authors:  Timothy J Nice; Megan T Baldridge; Broc T McCune; Jason M Norman; Helen M Lazear; Maxim Artyomov; Michael S Diamond; Herbert W Virgin
Journal:  Science       Date:  2014-11-27       Impact factor: 47.728

Review 6.  Structural analysis of cytokines comprising the IL-10 family.

Authors:  Alexander Zdanov
Journal:  Cytokine Growth Factor Rev       Date:  2010-09-16       Impact factor: 7.638

7.  An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities.

Authors:  Eyal Kalie; Diego A Jaitin; Renne Abramovich; Gideon Schreiber
Journal:  J Biol Chem       Date:  2007-02-19       Impact factor: 5.157

8.  Human interferon-lambda3 is a potent member of the type III interferon family.

Authors:  C Dellgren; H H Gad; O J Hamming; J Melchjorsen; R Hartmann
Journal:  Genes Immun       Date:  2008-11-06       Impact factor: 2.676

9.  Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B).

Authors:  Henry L Y Chan; Sang Hoon Ahn; Ting-Tsung Chang; Cheng-Yuan Peng; David Wong; Carla S Coffin; Seng Gee Lim; Pei-Jer Chen; Harry L A Janssen; Patrick Marcellin; Lawrence Serfaty; Stefan Zeuzem; David Cohen; Linda Critelli; Dong Xu; Megan Wind-Rotolo; Elizabeth Cooney
Journal:  J Hepatol       Date:  2015-12-29       Impact factor: 25.083

10.  Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.

Authors:  Martin J Boulanger; Dar-chone Chow; Elena E Brevnova; K Christopher Garcia
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

View more
  43 in total

1.  Genomic variability of within-host hepatitis C variants in acute infection.

Authors:  Chaturaka Rodrigo; Preston Leung; Andrew R Lloyd; Rowena A Bull; Fabio Luciani; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Julie Bruneau; Andrea L Cox; William Osburn; Arthur Y Kim; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Janke Schinkel; Maria Prins; Margaret Hellard; Auda A Eltahla
Journal:  J Viral Hepat       Date:  2019-01-22       Impact factor: 3.728

2.  Molecular engineering strategies for visualizing low-affinity protein complexes.

Authors:  Qianqian Ming; David Gonzalez-Perez; Vincent C Luca
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-11

Review 3.  The molecular details of cytokine signaling via the JAK/STAT pathway.

Authors:  Rhiannon Morris; Nadia J Kershaw; Jeffrey J Babon
Journal:  Protein Sci       Date:  2018-12       Impact factor: 6.725

Review 4.  Type III IFNs: Beyond antiviral protection.

Authors:  Sergei V Kotenko; Amariliz Rivera; Dane Parker; Joan E Durbin
Journal:  Semin Immunol       Date:  2019-06       Impact factor: 11.130

5.  Kinetics of cytokine receptor trafficking determine signaling and functional selectivity.

Authors:  Jonathan Martinez-Fabregas; Stephan Wilmes; Luopin Wang; Majid Kazemian; Suman Mitra; Ignacio Moraga; Maximillian Hafer; Elizabeth Pohler; Juliane Lokau; Christoph Garbers; Adeline Cozzani; Paul K Fyfe; Jacob Piehler
Journal:  Elife       Date:  2019-11-27       Impact factor: 8.140

6.  IL-1 Family Cytokines Use Distinct Molecular Mechanisms to Signal through Their Shared Co-receptor.

Authors:  Sebastian Günther; Daniel Deredge; Amanda L Bowers; Alessandra Luchini; Daniel A Bonsor; Robert Beadenkopf; Lance Liotta; Patrick L Wintrode; Eric J Sundberg
Journal:  Immunity       Date:  2017-09-19       Impact factor: 31.745

7.  Human Cervical Epithelial Cells Release Antiviral Factors and Inhibit HIV Replication in Macrophages.

Authors:  Xi-Qiu Xu; Le Guo; Xu Wang; Yu Liu; Hang Liu; Run-Hong Zhou; Jun Gu; Jin-Biao Liu; Pei Xu; Li Zhou; Wen-Zhe Ho
Journal:  J Innate Immun       Date:  2018-07-20       Impact factor: 7.349

8.  Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses.

Authors:  Claire Gorby; Junel Sotolongo Bellón; Stephan Wilmes; Walid Warda; Elizabeth Pohler; Paul K Fyfe; Adeline Cozzani; Christophe Ferrand; Mark R Walter; Suman Mitra; Jacob Piehler; Ignacio Moraga
Journal:  Sci Signal       Date:  2020-09-15       Impact factor: 8.192

9.  Differential Responses by Human Respiratory Epithelial Cell Lines to Respiratory Syncytial Virus Reflect Distinct Patterns of Infection Control.

Authors:  Philippa Hillyer; Rachel Shepard; Megan Uehling; Mina Krenz; Faruk Sheikh; Kalyn R Thayer; Lei Huang; Lihan Yan; Debasis Panda; Cindy Luongo; Ursula J Buchholz; Peter L Collins; Raymond P Donnelly; Ronald L Rabin
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

10.  Intranasal Bifidobacterium longum protects against viral-induced lung inflammation and injury in a murine model of lethal influenza infection.

Authors:  David Groeger; Elisa Schiavi; Ray Grant; Magdalena Kurnik-Łucka; David Michalovich; Rick Williamson; Soren Beinke; Barry Kiely; Cezmi A Akdis; Edith M Hessel; Fergus Shanahan; Liam O' Mahony
Journal:  EBioMedicine       Date:  2020-09-11       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.